Recent posts

TypePostAuthorRepliesLast updated
Blog entryBiden presses Colombia to block biosimilar drugs James Love02 days 12 hours ago
Blog entryWIPO's new Senior Management Team: New faces for Copyright, Development, Global Issues and Patents thiru03 days 12 hours ago
Blog entryKEI welcomes the Gilead HCV licenses, as a step to expand access to treatments. Notes challenges that remain KEI Staff04 days 11 hours ago
Blog entryThe Gilead HCV license: Glass half empty, or half full? James Love04 days 12 hours ago
Blog entrySenate HELP subcommittee hearings on S.1138, the HIV/AIDS prize fund James Love01 week 3 days ago
Blog entrySenator Wyden in 2012, on access to the TPP text Claire Cassedy01 week 3 days ago
Book pageFunding James Love01 week 3 days ago
PageDonate to KEI James Love02 weeks 1 day ago
Blog entryWIPO General Assembly 2014: Hard Decisions on the Broadcast Treaty and work program on copyright limitations and exceptions thiru02 weeks 2 days ago
Blog entryWIPO General Assembly 2014: Hard Decisions on the Design Law Treaty and Treaty for Protection of Genetic Resources thiru02 weeks 3 days ago
Blog entryJanuary 2013: Proposal for the inclusion of trastuzumab in WHO EML for treatment of HER2-Positive Breast Cancer thiru02 weeks 4 days ago
Blog entry13 May 2014: WHO Technical Consultation on Innovative Models for New Antibiotics’ Development and Preservation thiru03 weeks 2 days ago
Blog entryTDR and the Pooled Fund for R&D: WHO demonstration projects and CEWG follow-up thiru04 weeks 4 days ago
PageThe Big Idea: Prizes to Stimulate R&D for New Medicines thiru04 weeks 6 days ago
Book pageJames Love, Director James Love04 weeks 6 days ago
Blog entryOMB's Revised Guidance on Appointment of Lobbyists to Federal Advisory Committees, Boards, and Commissions James Love05 weeks 8 hours ago
Book pageCPTech's 2003 reports for the RSA Competition Commission, in Hazel Tau et al.v GSK, Boehringer, et al KEI Staff05 weeks 2 days ago
PageThe USTR Special 301 Reports, 1989 to 2014 James Love05 weeks 3 days ago
Blog entryGilead's US patient access programs for Sovaldi Elizabeth Rajasingh05 weeks 5 days ago
Blog entrySome recent cancer drug prices James Love06 weeks 4 days ago
Blog entryMoney speaks: USTR releases letters from Congress backing PhRMA on exclusive rights biologic test data in TPP KEI Staff06 weeks 5 days ago
Blog entryUS proposal: IGC Work Plan for 2015-Is the IGC train leaving the station? thiru06 weeks 5 days ago
Blog entryGilead's MPP license for tenofovir alafenamide (TAF) patents James Love07 weeks 1 day ago
PageElizabeth Rajasingh, Perls Fellow Elizabeth Rajasingh07 weeks 2 days ago
Book pageHepatitis C Claire Cassedy07 weeks 2 days ago